Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | BRAF | P15056 | 7/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319466 | 0.91 | LMNA (0.39) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319897 | 0.91 | IGF1R (0.45) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319899 | 0.91 | TEK (0.46) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319852 | 0.91 | TEK (0.46) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319723 | 0.89 | TEK (0.44) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319616 | 0.89 | TEK (0.46) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319967 | 0.89 | TEK (0.45) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16320016 | 0.89 | TEK (0.45) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319853 | 0.89 | TEK (0.45) | TEKKDRBRAFMAPK14CDK8 | |
| SCHEMBL16319950 | 0.88 | TEK (0.46) | TEKKDRBRAFMAPK14CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221798-B2 | 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof | Zhejian Hisun Pharmaceutical Co., Ltd. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | MAP4K2, MAP4K1, MAP4K3 | TEK 984/4885KDR 550/4885BRAF 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.